JW Therapeutics Co., Ltd

China’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Helsinn Extends Akynzeo Marketing

Chinese drug makers have made both major cuts and additions to their R&D pipelines in recent months, including for antibody-drug conjugates (ADCs) amid increasingly fierce competition, a Scrip revie

Chinese immuno-oncology specialist CARsgen Therapeutics and Huadong Medicine Co., Ltd. , its domestic commercialization partner, on 1 March won regulatory approval in China for zevorcabtagene autol